Factor IX Gene Therapy Codon Optimization for Hemophilia B

The patent applies gene therapy to create a functional copy of the Factor IX gene within the patient's genome. This genetic copy enables endogenous production of Factor IX protein, replacing the need for continuous external protein administration. The copied gene is integrated into the patient's DNA and directs the patient's own cells to produce the therapeutic protein, achieving a curative effect that eliminates long-term treatment costs while maintaining reliable bleeding control.

The patent employs codon optimization to modify the nucleotide sequence of the Factor IX gene, changing the coding parameters to enhance translation efficiency. Specifically, the codons are optimized to match the preferred codon usage of the target host cells, thereby increasing the expression level of Factor IX protein. This parameter change in the genetic code enables high-level protein production from the gene therapy vector, achieving both reduced injection frequency and high productivity.

The patent applies local quality by selectively optimizing specific regions of the Factor IX gene while maintaining other regions as wild type. The coding sequence is optimized for expression in the host system, while critical functional domains and regulatory elements are preserved in their original wild type form. This localized optimization approach ensures that expression level is enhanced in the optimized regions without compromising the protein activity encoded by the maintained wild type portions, achieving both high productivity and reliable protein function.